Windward Bio has raised $175 million in its US initial public offering, adding to a growing pipeline of healthcare and biotechnology companies tapping public markets as listings in other sectors face pressure from economic uncertainty.
The Basel, Switzerland-based drug developer sold approximately 10.3 million shares at $17 each, within its marketed range of $16 to $18. Its shares are scheduled to begin trading on Friday on the Nasdaq under the ticker symbol WWB.
The offering gives Windward fresh capital to advance its experimental antibody medicines for serious respiratory and dermatological diseases, with its lead programme targeting conditions that affect millions of patients worldwide. The company is backed by Novo Holdings, alongside other healthcare investors, and has attracted a $50 million commitment from French pharmaceutical group Sanofi.
Register for the next Tekedia Mini-MBA.
Register for Tekedia AI in Business Masterclass.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Sanofi agreed to purchase $50 million in shares and pre-funded warrants through a private placement, providing Windward with an additional source of institutional backing as it enters the public market. The investment also gives the pharmaceutical group exposure to a biotechnology company developing treatments in areas where demand for new therapies remains significant.
Windward’s lead candidate, WIN378, is being developed for asthma and chronic obstructive pulmonary disease, or COPD. The antibody is designed to block a protein involved in airway inflammation, an approach intended to address an underlying biological mechanism contributing to both conditions.
The programme will be central to the company’s development strategy as it moves into the public market. However, WIN378 remains an experimental medicine, and its commercial prospects will depend on clinical results, regulatory approvals and its ability to demonstrate meaningful benefits over existing treatments.
Led by founder and chief executive Luca Santarelli, Windward has raised $310 million in equity financing from Novo Holdings and other healthcare investors, including OrbiMed, Blue Owl and RTW Investments.
Santarelli has previously built biotechnology businesses that attracted substantial acquisition interest from larger pharmaceutical companies. VectivBio, one of his earlier ventures, was acquired by Ironwood Pharmaceuticals for $1.2 billion in 2023. Pfizer acquired another company he was associated with, Therachon, in 2019 for $810 million.
That history provides Windward with a management team familiar with biotechnology development and the commercial pressures facing companies seeking to bring new medicines to market. However, previous acquisitions do not guarantee that its current drug candidates will achieve similar outcomes.
The company’s IPO also underscores the importance of specialist healthcare investors in financing drug development. Biotechnology companies often require substantial capital over several years before generating commercial revenue, as clinical trials, regulatory submissions, and manufacturing preparations result in costs well ahead of product launches.
Public listings can provide access to a broader pool of capital, but they also expose early-stage drug developers to market volatility and greater scrutiny of clinical progress. For Windward, the challenge will be to use its new funding to advance its pipeline while showing that its scientific approach can translate into viable treatments.
Windward’s listing comes during a period of renewed activity among healthcare and biotechnology companies seeking to enter US public markets. The sector has accounted for a series of listings this autumn, even as macroeconomic headwinds have weakened IPO activity in other industries.
The contrast indicates that investor appetite for new listings remains selective rather than broadly restored. Companies with specialized healthcare programmes and established institutional backing have found opportunities to raise capital, while uncertainty over economic conditions and market valuations continues to weigh on other potential issuers.
For biotechnology businesses, the appeal of public markets is closely tied to the need for long-term financing. Unlike companies with established cash-generating operations, drug developers must often fund research and clinical trials before they can establish whether a candidate has commercial potential. A successful IPO can extend their financial runway and support development milestones that may improve their prospects of securing partnerships or attracting acquisition interest.
Still, investors face considerable risks. Drug candidates can fail in clinical trials, regulatory authorities can request additional evidence, and even approved treatments may struggle to gain market share. These make Windward’s valuation depend not only on its scientific programmes but also on the pace and quality of clinical data it produces.
Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank are underwriting the offering.
Another Swiss healthcare-related company, dental firm vVardis, is also expected to go public on Friday. Its planned listing alongside Windward would add to the week’s activity and provide another indication of investor demand for companies operating in specialized healthcare markets.